Loading
Only a handful of insider records exist for Astellas Pharma Inc., the last one from 20 January 2026, too few to describe a trend. Every figure here comes from the filings published by EDINET (Japan FSA) and describes the past, not future prices; it is not investment advice.
Analysts rate Astellas Pharma Inc. Buy (bullish), based on 14 analysts. Average price target: JP¥2,529.
Transparent value + quality ranking, distinct from the insider signal.
FY ended March 2026 · cache
11 of 11 declarations
Astellas Pharma Inc. is a Japanese pharmaceutical company focused on the research and development of innovative medicines. It primarily concentrates on oncology, urology, and infectious diseases.
Headquarters: Chūō, Japan · Founded: 2005 · Wikipedia article
Source: Wikidata (CC0).